The 80% Number Isn’t a Customer Service Problem. It’s a Compliance Finding.
MA plans overturn four out of five of their own reconsiderations. Under the 2026 ODAG integrated CPE framework, CMS now asks what the compliance function knows about that rate.
Scroll to readPlans track timeliness. They track volume. Almost none track the overturn rate as a compliance metric — which is what CMS’s integrated CPE review is designed to surface it as.
MA plans track appeals volume. They track timeliness. Some track overturn rates — usually as a member experience signal or a process efficiency concern. Almost none track overturn rates as a compliance metric. That framing is about to become difficult to sustain.
CMS’s 2026 integrated compliance program effectiveness framework places the compliance officer inside ODAG fieldwork. When CMS auditors review organization determinations, appeals, and grievances under the new model, the compliance function is expected to explain in real time what monitoring it conducts, what patterns it identifies, and what corrective action it takes without external pressure.
The 80% plan-level reconsideration overturn rate — confirmed in KFF analysis of CMS data — is the kind of pattern that compliance monitoring is supposed to surface. If a plan overturns four out of five of its own initial decisions on appeal, that is not a process throughput problem. It is evidence of systematic error at the determination stage. Under the new audit framework, the compliance officer needs to be prepared to say what the organization knows about that error rate, what it has done about it, and why it has not already corrected itself. That is a different question than any MA plan’s A&G compliance program has had to answer before.
KFF’s analysis of CMS Medicare Advantage appeal data shows that plans overturn 80% of denied requests at the plan-level reconsideration stage. A related figure — 80.7% — reflects the share of appealed denials that were partially or fully overturned across the years KFF examined. These numbers are often cited as evidence that the MA appeals process works: enrollees who fight their denials usually win. That framing misses the more important implication.
If a plan reverses its own decision four out of five times on appeal, the initial decision was wrong four out of five times. The appeals process did not produce a good outcome — it corrected a bad upstream decision. The compliance significance is different from the member access significance.
From a member access perspective, the overturn rate is concerning because most denials are never appealed. KFF’s data consistently shows that a small fraction of denied requests actually proceed through the appeals process — which means the majority of incorrect initial determinations are never corrected at all. The appeals system catches a fraction of the errors. Compliance monitoring is supposed to catch the rest.
From a compliance perspective, the overturn rate at plan reconsideration is a diagnostic signal about the quality of the organization determination process. CMS’s ODAG audit protocol evaluates whether plans are making coverage decisions that are medically appropriate, timely, and correctly classified. A plan that overturns 80% of its own reconsiderations has, by its own internal review, determined that 80% of its initial decisions were wrong. That is a finding about the upstream determination process — not a separate administrative metric.
CMS’s 2024 Part C and Part D Program Audit and Enforcement Report identified coverage request misclassification as a recurring ODAG finding: requests dismissed or miscategorized before triggering the required determination process. The overturn rate data, read alongside that finding, indicates a structural alignment problem between how plans process determination requests and what CMS’s ODAG protocol requires. Under the integrated CPE model active in 2026 audits, CMS will be in the room to ask compliance officers what their monitoring detected — and what was done about it.
The IRE handoff is live. The compliance record it creates isn’t starting fresh.
Source: CMS Part C IRE page; CMS 2024 Part C and Part D Program Audit and Enforcement Report; CMS Program Audits Annual Update 2026
Three things compliance and operations leaders need to address now
The 80% reconsideration overturn rate, the IRE transition, and the integrated CPE review model create three distinct but connected obligations for compliance and operations teams managing ODAG in 2026.
Treat the overturn rate as a compliance diagnostic, not a process metric
The overturn rate at plan reconsideration is a direct indicator of initial determination quality. A compliance program that monitors ODAG timeliness and case volume but does not systematically analyze why reconsideration decisions reverse initial determinations is missing the most informative signal in its own data. Under integrated CPE review, CMS will ask what the compliance function knows about the patterns behind overturn decisions — what diagnosis codes, service types, or clinical criteria are driving reversals, and what corrective action those patterns have produced. Plans that cannot answer this question have a gap between their monitoring capability and what CMS now expects to hear.
Map the IRE pipeline across both MAXIMUS and C2C
Plans with cases in the MAXIMUS pipeline from before May 1 and new cases routing to C2C need a clean accounting of where each case sits, what documentation has been submitted, and what decisions are pending. The transition does not pause the compliance clock. Adverse IRE decisions from either entity are binding and require plan-level action. If your operations team is managing the transition as a routing update, compliance needs to be tracking it as a dual-entity caseload management challenge with audit implications.
Audit grievance classification logic now, not after an engagement letter arrives
Grievance misclassification — routing coverage requests into grievance workflows, or dismissing requests before they enter the determination process — is the most consistently cited ODAG finding in CMS’s enforcement record. It is also the error most likely to be invisible to IRE review, because misclassified cases never reach the appeals chain. Under the 2026 audit model, CMS auditors will review the plan’s universe submission for the ODAG domain and cross-reference it against CMS’s own classification of the same cases. Plans that have not conducted a classification audit of their recent determination intake are likely holding unidentified ODAG exposure.
The compliance significance of the 80% overturn rate is not that it is too high — though it is. The significance is that it is diagnostic. It means the initial determination process is producing incorrect decisions at a rate that the plan’s own appeals process repeatedly confirms. Under the 2026 audit framework, that confirmation is visible to CMS. The compliance function is responsible for explaining what it did with that information before CMS arrived to ask.
A plan that overturns 80% of its own reconsiderations has, by its own internal review, determined that 80% of its initial decisions were wrong. That is a finding about the upstream determination process — not a separate administrative metric.
PCOOB Weekly — May 22, 2026Why this matters — by function
Integrated CPE means you are in the room during ODAG fieldwork
The 2026 audit framework places the compliance officer inside ODAG review. You need to speak to monitoring cadence, root cause analysis, and corrective action in the determination domain — not just produce policy documentation when asked.
The overturn rate is now a compliance data point, not just an ops metric
Operations teams that track overturn rates without feeding findings back into a compliance analysis cycle are producing data that compliance cannot use. The 2026 model requires that loop to close before fieldwork begins.
C2C brings a new review relationship, not just a new vendor number
The IRE’s interpretation tendencies, documentation expectations, and data requests will differ from MAXIMUS’s. Legal teams need to build C2C-specific knowledge, not assume continuity from the prior review relationship.
Determination reversal patterns reveal clinical criteria misapplication
When reconsiderations consistently reverse initial determinations for specific service types or diagnosis codes, that pattern identifies where clinical decision criteria are being misapplied at intake. Clinical operations must be in the loop on that data.
Universe submission completeness is testable under the 2026 IDS classification
CMS introduced the Invalid Data Submission classification in 2026 for plans that cannot provide accurate or complete ODAG universes during fieldwork. System configuration errors — like PA systems misrouting appeal requests as initial requests — are universe integrity problems, not just operational errors.
The 80% rate is visible to CMS under the integrated CPE model
Under prior audit frameworks, the reconsideration overturn rate was an internal operational metric. Under the 2026 integrated CPE model, it is visible to CMS during ODAG fieldwork. Executive leaders need to understand that the compliance story CMS is looking for connects determination quality to compliance monitoring to corrective action.
Questions leaders should be asking now
Does our compliance function know the current reconsideration overturn rate, broken down by service type and clinical criteria applied? Have those patterns produced any corrective action?
Do we have a clean accounting of which appeal cases are at MAXIMUS and which are routing to C2C? Does compliance know the status of cases pending at both entities?
Have we conducted a grievance classification audit in the last 90 days? Do we know how many coverage requests were routed into grievance workflows or dismissed before entering the determination process?
Is the compliance officer who will participate in ODAG fieldwork conversant in the determination quality data — not just the timeliness metrics — for the ODAG domain?
What monitoring does our compliance function run between audit cycles on the ODAG domain? Is that monitoring producing findings, and are those findings being closed before CMS arrives?
Has our universe submission been reviewed for completeness and accuracy across all ODAG case types before the audit window? Are our system configurations correctly routing all request types?
- MA plans overturn approximately 80% of denied requests at plan-level reconsideration, per KFF analysis of CMS data. Under integrated CPE review, CMS will ask what the compliance function knows about that rate and what corrective action it produced.
- Effective May 1, 2026, C2C Innovative Solutions is the Part C IRE. Plans are managing dual-entity caseloads — MAXIMUS for pre-May 1 cases, C2C for new cases — while potentially under active ODAG engagement letters.
- Grievance misclassification — routing coverage requests into grievance workflows or dismissing requests before they trigger the determination process — is the most consistently cited ODAG finding in CMS’s enforcement record.
- CMS’s 2024 enforcement report identified coverage request misclassification as a recurring ODAG finding, with cases dismissed due to insufficient internal processes. Plans without a recent classification audit are likely holding unidentified exposure.
- The 80% overturn rate is diagnostic, not just operationally significant. It is evidence that initial determinations fail at scale — and under 2026 integrated CPE, that evidence is visible to CMS during ODAG fieldwork.
Sources
-
1
KFF — Medicare Advantage Appeal Data Analysis Confirms: MA plans overturn 80%+ of denied requests at plan-level reconsideration; 80.7% of appealed denials partially or fully overturned; low share of denied requests actually appealed. Tier 2.
-
2
CMS — Reconsideration by Part C Independent Review Entity Confirms: C2C Innovative Solutions became Part C IRE effective May 1, 2026; MAXIMUS continues processing requests received on or before April 30, 2026; C2C handles requests received on or after May 1. Tier 1.
-
3
CMS — 2024 Part C and Part D Program Audit and Enforcement Report Confirms: Coverage request misclassification identified as recurring ODAG finding; cases dismissed due to insufficient internal processes; grievance misclassification as a systematic vulnerability. Tier 1.
-
4
CMS — Program Audits 2026 Annual Update Confirms: 2026 audit season February through August; integrated CPE review embedded in program area audits including ODAG; new IDS classification for documentation failures. Tier 1.
-
5
AHA News — CMS Awards New Contract for Independent Reviews of MA Adverse Organization Determinations and Reconsiderations Confirms: CMS contract award to C2C Innovative Solutions; MAXIMUS transition timeline; plan notification requirements. Tier 2.